3′-deoxy-3′- 18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab

Journal of Nuclear Medicine

Volumn 53, Issue 1, 2012, Pages 29-36

  Schwarzenberg, Johannes ^a,b   Czernin, Johannes ^a   Cloughesy, Timothy F ^a   Ellingson, Benjamin M ^c   Pope, Whitney B ^c   Geist, Cheri ^a   Dahlbom, Magnus ^a   Silverman, Daniel H S ^a   Satyamurthy, Nagichettiar ^a   Phelps, Michael E ^a   Chen, Wei ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

18F FLT PET; Bevacizumab; Malignant glioma; Survival prediction

Indexed keywords

3' FLUOROTHYMIDINE F 18; BEVACIZUMAB; CORTICOSTEROID; DEXAMETHASONE; IRINOTECAN; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; GLIOBLASTOMA; HAZARD RATIO; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; KAPLAN MEIER METHOD; MALE; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECURRENT CANCER; TREATMENT RESPONSE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GLIOMA; METABOLISM; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; TIME; TRANSPORT AT THE CELLULAR LEVEL; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL TRANSPORT; DIDEOXYNUCLEOSIDES; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84855405944     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.092387     Document Type: Article

References (39)

1. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999; 17:2572-2578. (Pubitemid 29368260)
2. Wen PY, Kesari S. Malignant gliomas in adults. N Engl JMed. 2008;359:492-507.
3. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011-1027. (Pubitemid 46202320)
4. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti- VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333:328-335. (Pubitemid 40848295)
5. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722-4729. (Pubitemid 350086473)
6. Raymond E, Fabbro M, Boige V, et al. Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma. Ann Oncol. 2003;14:603-614. (Pubitemid 41295091)
7. Prados MD, Lamborn K, Yung WKA, et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-oncol. 2006;8:189-193. (Pubitemid 46542664)
8. Ballman KV, Buckner JC, Brown PD, et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro-oncol. 2007;9:29-38. (Pubitemid 46543486)
9. Narayana A, Kelly P, Golfinos J, et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg. 2009;110:173-180.
10. Friedman HS, Prados MD,Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733-4740.
11. Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase-II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280. (Pubitemid 20195640)
12. Levivier M, Becerra A, DeWitte O, Brotchi J, Goldman S. Radiation necrosis or recurrence. J Neurosurg. 1996;84:148-149.
13. van den Bent MJ, Vogelbaum MA, Wen PY, Macdonald DR, Chang SM. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's criteria. J Clin Oncol. 2009;27:2905-2908.
14. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J Clin Oncol. 2010;28:1963-1972.
15. Ellingson B, Cloughesy T, Lai A, Nghiemphu P, Mischel P, Pope W. Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. Neuro-Oncology. 2011;13:401-409.
16. Alavi JB, Alavi A, Chawluk J, et al. Positron emission tomography in patients with glioma: a predictor of prognosis. Cancer. 1988;62:1074-1078.
17. Wong TZ, van der Westhuizen GJ, Coleman RE. Positron emission tomography imaging of brain tumors. Neuroimaging Clin N Am. 2002;12:615-626. (Pubitemid 36015495)
18. Ricci PE, Karis JP, Heiserman JE, Fram EK, Bice AN, Drayer BP. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? AJNR. 1998;19:407-413. (Pubitemid 30422740)
19. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336. (Pubitemid 28512118)
20. Chen W, Delaloye S, Silverman DHS, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [F-18] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25:4714-4721. (Pubitemid 350086472)
21. Blocher A, Kuntzsch M, Wei R, Machulla HJ. Synthesis and labeling of 5′-O-(4,4′-dimethoxytrityl)-2,3′-anhydrothymidine for [F-18]FLT preparation. J Radioanal Nucl Chem. 2002;251:55-58. (Pubitemid 34145401)
22. Kaplan EL, Meier P. Nonparametric-estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
23. Cox DR. Regression models and life-tables. J R Stat Soc, B. 1972;34:187-202.
24. 18F- Fluoroethyl)-L-tyrosine PET predicts failure of antiantiogenic treatment in patients with recurrent highgrade glioma. J Nucl Med. 2011;52:856-864.
25. Port RE, Bernstein LJ, Barboriak DP, Xu L, Roberts TPL, van Bruggen N. Noncompartmental kinetic analysis of DCE-MRI data from malignant tumors: application to glioblastoma treated with bevacizumab. Magn Reson Med. 2010; 64:408-417.
26. Gonzalez J, Kumar AJ, Conrad CA, Levin VA. Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys. 2007;67:323-326. (Pubitemid 46108339)
27. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58-62. (Pubitemid 40093472)
28. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002;20:4368-4380. (Pubitemid 35266299)
29. de Groot JF, Fuller G, Kumar AJ, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro-oncol. 2010;12:233-242.
30. Pope WB, Kim HJ, Huo J, et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009;252:182-189.
31. Sorensen AG, Batchelor TT, Zhang WT, et al. A "vascular normalization index"as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 2009;69:5296-5300.
32. Chen W, Cloughesy T, Kamdar N, et al. Imaging proliferation in brain tumors with F-18-FLT PET: comparison with F-18-FDG. J Nucl Med. 2005;46:945-952. (Pubitemid 43733508)
33. Ullrich R, Backes H, Li H, et al. Glioma proliferation as assessed by 3′-fluoro-3′-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin Cancer Res. 2008;14:2049-2055. (Pubitemid 351551115)
34. 11C-methyl-methionine as markers of increased transport and proliferation in brain tumors. J Nucl Med. 2005;46:1948-1958.
35. 18F-fluorothymidine kinetics of malignant brain tumors. Eur J Nucl Med Mol Imaging. 2007;34:1003-1011.
36. 18F]FLT PET for non-invasive monitoring of early response to gene therapy in experimental gliomas. Mol Imaging Biol. 2011; 13:547-557.
37. Jacobs AH, Rueger MA, Winkeler A, et al. Imaging-guided gene therapy of experimental gliomas. Cancer Res. 2007;67:1706-1715. (Pubitemid 46383397)
38. Galldiks N, Kracht LW, Burghaus L, et al. Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma. Mol Imaging. 2010;9:40-46.
39. 18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma. J Nucl Med. 2010;51:720-727.